Callan Family Office LLC Acquires 19,884 Shares of Eli Lilly and Company $LLY

Key Points

• Callan Family Office LLC significantly increased its stake in Eli Lilly by acquiring an additional 19,884 shares, bringing its total holdings to 42,810 shares, valued at approximately $33.37 million.
• Multiple institutional investors, including WestEnd Advisors LLC and TD Capital Management LLC, have also substantially increased their positions in Eli Lilly, highlighting strong interest in the company's stock.
• Eli Lilly reported a substantial quarterly earnings increase with a revenue of $15.56 billion, exceeding expectations and posting a 37.6% year-over-year growth.

Callan Family Office LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 86.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,810 shares of the company's stock after buying an additional 19,884 shares during the period. Eli Lilly and Company accounts for about 1.1% of Callan Family Office LLC's investment portfolio, making the stock its 14th biggest holding. Callan Family Office LLC's holdings in Eli Lilly and Company were worth $33,371,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. WestEnd Advisors LLC grew its holdings in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, TD Capital Management LLC grew its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. HSBC boosted their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the company an "overweight" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $948.56.

Eli Lilly and Company Stock Up 1.0%

Eli Lilly and Company stock opened at $854.40 on Friday. The stock has a market capitalization of $808.66 billion, a PE ratio of 55.84, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a 50 day moving average of $740.99 and a 200-day moving average of $766.49.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.